US · NYXH
Nyxoah S.A.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Mont-Saint-Guibert 1435
- Website
- nyxoah.com
Price · as of 2024-12-31
$3.00
Market cap 152.37M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.00 | +966.67% |
| Intrinsic Value(DCF) | $4.45 | +48.33% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $18.51 | $163.93 | $5.16 | $0.50 | $0.00 |
| 2022 | $5.26 | $52.68 | $2.86 | $0.00 | $0.00 |
| 2023 | $16.02 | $30.74 | $0.00 | $0.00 | $0.00 |
| 2024 | $10.01 | $27.36 | $0.81 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Nyxoah S.A.'s (NYXH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.00
- Current price
- $3.00
- AI upside
- +966.67%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.45
+48.33% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NYXH | Nyxoah S.A. | $3.00 | 152.37M | +812% | +48% | — | — | -4.96 | 2.47 | 61.97 | -3.74 | -29.59 | 4.46 | 65.67% | -1300.80% | -1310.24% | -53.42% | -113.83% | -39.94% | 0.20 | -30.90 | 4.56 | 4.13 | 0.20 | 1677.00% | 398.00% | -79.00% | -19.74% | -2.29 | -107.03% | 0.00% | 0.00% | 0.94% | -3.69 | -3.93 | 48.05 | 1.18 |
| GNFT | Genfit S.A. | $10.00 | 497.97M | +550% | -76% | -82% | -52% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| IVVD | Invivyd, Inc. | $1.69 | 224.31M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| KRMD | KORU Medical Systems, Inc… | $4.77 | 220.96M | +739% | -5% | — | — | -23.86 | 8.61 | 4.30 | -24.53 | — | 9.00 | 63.40% | -19.16% | -18.03% | -32.64% | -52.54% | -21.79% | 0.24 | — | 2.66 | 2.16 | 0.99 | -5667.00% | 1798.00% | -7166.00% | -1.12% | -0.04 | -13.18% | 0.00% | 0.00% | 0.07% | -21.59 | -86.04 | 4.14 | 7.82 |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| OSUR | OraSure Technologies, Inc… | $3.15 | 230.38M | +1,022% | -63% | — | +744% | -3164.74 | 0.64 | 1.89 | -3.83 | -1210.05 | 0.64 | 41.90% | -59.23% | -59.76% | -0.02% | -27.37% | -0.02% | 0.00 | — | 6.58 | 0.01 | 0.00 | 26154.00% | -3810.00% | -10023.00% | -0.02% | 0.00 | -0.02% | 0.00% | 0.00% | 6.91% | -3.19 | -4083.36 | 1.89 | 2.48 |
| PRE | Prenetics Global Limited | $16.91 | 237.65M | +204% | +11,114% | — | — | -4.22 | 1.27 | 2.41 | -4.86 | -30.15 | 1.71 | 52.98% | -40.46% | -63.13% | -30.55% | -32.70% | -25.27% | 0.01 | -155.12 | 3.01 | 2.33 | 0.89 | 1401.00% | 20172.00% | -2645.00% | -9.89% | -0.79 | -19.26% | 0.00% | 0.00% | 0.00% | -4.37 | -7.42 | 1.77 | 4.78 |
| STIM | Neuronetics, Inc. | $1.34 | 91.77M | +1,696% | +34,643% | — | — | -3.68 | 5.81 | 2.15 | -6.51 | -11.71 | -15.27 | 72.32% | -46.15% | -58.36% | -141.29% | -54.52% | -34.06% | 2.98 | -4.74 | 1.86 | 1.41 | -1.84 | 3143.00% | 496.00% | -565.00% | -20.18% | -0.99 | -51.22% | 0.00% | 0.00% | 0.00% | -6.48 | -6.90 | 2.99 | -3.34 |
| TARA | Protara Therapeutics, Inc… | $6.36 | 245.43M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
| UTMD | Utah Medical Products, In… | $66.61 | 213.4M | +632% | -36% | -27% | -87% | 19.68 | 1.86 | 5.77 | 7.99 | — | 2.13 | 51.60% | 29.60% | 29.30% | 9.54% | 26.71% | 9.21% | 0.00 | — | 37.62 | 34.36 | -5.03 | -1212.00% | -583.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 1.38% | 11.96 | — | 3.54 | 42.25 |
About Nyxoah S.A.
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- CEO
- Olivier Taelman
- Employees
- 183
- Beta
- 0.65
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.45 ÷ $3.00) − 1 = +48.33% (DCF, example).